Erratum: Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease (Blood Advances (2017) 1:20 (1645-1649) DOI: 10.1182/bloodadvances.2017009613)

J. J. Field; E. Majerus; V. R. Gordeuk

doi:10.1182/bloodadvances.2017012922

Erratum: Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease (Blood Advances (2017) 1:20 (1645-1649) DOI: 10.1182/bloodadvances.2017009613)

J. J. Field, E. Majerus, V. R. Gordeuk

Research output: Contribution to journal › Comment/debate

Abstract

In the "Acknowledgments" section on page 1648 of the 12 September 2017 issue, an acknowledgment of support from Charles T. Quinn, Jeffrey Keefer, Paul Swerdlow, and Marilyn Telen was missing. Also, the author initials associated with grants R01 HL098526 and P50HL110790 should have been excluded, because the grants funded more individuals than originally indicated. The errors have been corrected in the published article.

Original language	English
Pages (from-to)	2058
Number of pages	1
Journal	Blood Advances
Volume	1
Issue number	23
DOIs	https://doi.org/10.1182/bloodadvances.2017012922
State	Published - Oct 24 2017

Access to Document

10.1182/bloodadvances.2017012922

Cite this

@article{8ae4c9cf5e954c9e87afc3e83efe5845,

title = "Erratum: Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease (Blood Advances (2017) 1:20 (1645-1649) DOI: 10.1182/bloodadvances.2017009613)",

abstract = "In the {"}Acknowledgments{"} section on page 1648 of the 12 September 2017 issue, an acknowledgment of support from Charles T. Quinn, Jeffrey Keefer, Paul Swerdlow, and Marilyn Telen was missing. Also, the author initials associated with grants R01 HL098526 and P50HL110790 should have been excluded, because the grants funded more individuals than originally indicated. The errors have been corrected in the published article.",

author = "Field, {J. J.} and E. Majerus and Gordeuk, {V. R.}",

note = "Publisher Copyright: {\textcopyright} 2017 by The American Society of Hematology.",

year = "2017",

month = oct,

day = "24",

doi = "10.1182/bloodadvances.2017012922",

language = "English",

volume = "1",

pages = "2058",

journal = "Blood Advances",

issn = "2473-9529",

number = "23",

}

TY - JOUR

T1 - Erratum

T2 - Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease (Blood Advances (2017) 1:20 (1645-1649) DOI: 10.1182/bloodadvances.2017009613)

AU - Field, J. J.

AU - Majerus, E.

AU - Gordeuk, V. R.

PY - 2017/10/24

Y1 - 2017/10/24

N2 - In the "Acknowledgments" section on page 1648 of the 12 September 2017 issue, an acknowledgment of support from Charles T. Quinn, Jeffrey Keefer, Paul Swerdlow, and Marilyn Telen was missing. Also, the author initials associated with grants R01 HL098526 and P50HL110790 should have been excluded, because the grants funded more individuals than originally indicated. The errors have been corrected in the published article.

AB - In the "Acknowledgments" section on page 1648 of the 12 September 2017 issue, an acknowledgment of support from Charles T. Quinn, Jeffrey Keefer, Paul Swerdlow, and Marilyn Telen was missing. Also, the author initials associated with grants R01 HL098526 and P50HL110790 should have been excluded, because the grants funded more individuals than originally indicated. The errors have been corrected in the published article.

UR - http://www.scopus.com/inward/record.url?scp=85073833959&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2017012922

DO - 10.1182/bloodadvances.2017012922

M3 - Comment/debate

C2 - 29297515

AN - SCOPUS:85073833959

SN - 2473-9529

VL - 1

SP - 2058

JO - Blood Advances

JF - Blood Advances

IS - 23

ER -

Erratum: Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease (Blood Advances (2017) 1:20 (1645-1649) DOI: 10.1182/bloodadvances.2017009613)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this